This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 170 for:    Willem
Previous Study | Return to List | Next Study

AI-powered ECG Analysis Using Willem™ Software in High-risk Cardiac Patients (WILLEM) (WILLEM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05890716
Recruitment Status : Recruiting
First Posted : June 6, 2023
Last Update Posted : June 8, 2023
Sponsor:
Collaborators:
Fundación de Investigación en Red en Enfermedades Cardiovasculares
Spanish Society of Cardiology
Information provided by (Responsible Party):
Idoven 1903 S.L.

Brief Summary:

WILLEM is a multi-center, prospective and retrospective cohort study.

The study will assess the performance of a cloud-based and AI-powered ECG analysis platform, named Willem™, developed to detect arrhythmias and other abnormal cardiac patterns. The main questions it aims to answer are:

  1. A new AI-powered ECG analysis platform can automatice the classification and prediction of cardiac arrhythmic episodes at a cardiologist level.
  2. This AI-powered ECG analysis can delay or even avoid harmful therapies and severe cardiac adverse events such as sudden death.

The prerequisites for inclusion of patients will be the availability of at least one ECG record in raw data, along with patient clinical data and evolution data after more than 1-year follow-up.

Cardiac electrical signals from multiple medical devices will be collected by cardiology experts after obtaining the informed consent. Every cardiac electrical signal from every subject will be reviewed by a board-certified cardiologist to label the arrhythmias and patterns recorded in those tracings. In order to obtain tracings of relevant information, >95% of the subjects enrolled will have rhythm disorders or abnormal ECG's patterns at the time of enrollment.


Condition or disease Intervention/treatment
Cardiomyopathies Cardiac Arrest Cardiac Arrhythmias Sudden Cardiac Death Diagnostic Test: AI-powered ECG analysis to detect cardiac arrhythmic episodes

Detailed Description:

The WILLEM study is an investigator-initiated, multicenter, observational trial aiming to validate a cloud-based AI-powered ECG analysis platform to early diagnose and predict the behavior of cardiac abnormalities and cardiac diseases from patients admitted to cardiovascular units. Model-derived diagnosis will be compared with cardiology expert's diagnosis in a test dataset. Clinical outcomes will be included to assess model prediction capabilities: sensitivity, specificity and accuracy. In this observational study, patients will be randomly divided into two groups: (1) a training group to design new methodologies and algorithms; and (2) a test group to evaluate performance of methodologies aiming to avoid overfitting.

Willem™ AI-powered ECG analysis platform supports the analysis of cardiac electrical signals ≥ 10 seconds onwards obtained from devices in-clinic (E.g., 12-lead ECG devices at hospitals or primary care, telemetries, monitors) and at-home or telemedicine interfaces (E.g., Holter devices, event recorders, 6, 3, 2, 1-lead ECG wearables, textile electrodes and patches for mobile cardiac telemetry).

Layout table for study information
Study Type : Observational
Estimated Enrollment : 5342 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Evaluation of Electrocardiographic Data From High-risk Cardiac Patients Using Willem™ Cardiologist-level Artificial Intelligence Software. WILLEM Trial.
Actual Study Start Date : April 4, 2023
Estimated Primary Completion Date : April 4, 2024
Estimated Study Completion Date : April 4, 2025

Group/Cohort Intervention/treatment
Train group
Consecutive patients admitted to the hospital due to cardiac disorders (retrospective and prospective) with at least one relevant ECG record >10 sec in raw data will be used to design new methodologies and algorithms for cardiac patterns recognition.
Diagnostic Test: AI-powered ECG analysis to detect cardiac arrhythmic episodes
ECG recording and processing by AI platform

Test group
Consecutive patients admitted to the hospital due to cardiac disorders (retrospective and prospective) with at least one relevant ECG record >10 sec in raw data will be used to evaluate performance of methodologies aiming to avoid overfitting. Every 10 patients included in Train group; a new patient is included in the test group.
Diagnostic Test: AI-powered ECG analysis to detect cardiac arrhythmic episodes
ECG recording and processing by AI platform




Primary Outcome Measures :
  1. Detection of cardiac arrhythmias and cardiac patterns in the electrocardiographic signals [ Time Frame: real time to 7 minutes ]
    Willem™ heart rhythm and cardiac pattern performance compared to standard manually performed cardiologist diagnosis.


Secondary Outcome Measures :
  1. Survival at follow-up [ Time Frame: 1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients) ]
    Patients alive at the time of follow-up

  2. Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) [ Time Frame: 1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients) ]
    MACCE rates defined as cardiovascular and cerebrovascular events during the follow up

  3. Re-hospitalization [ Time Frame: 1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients) ]
    Number of Re-hospitalizations during the follow up.

  4. Change in quality of life [ Time Frame: 1 year after the first ECG (prospective patients) or after patient enrollment (retrospective patients) ]
    European Quality of Life-5 Dimensions (EQ-5D) index an utility scores anchored at 0 for death and 1 for perfect health.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   4 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Patients recorded with a mid to long-term ECG device according to guidelines. ECG data (ECG must have been recorded according to the technical standards for the safety and essential performance of medical electrical equipment defined in EN 60601-2-47:2015.): 12-lead ECGs including rest electrocardiograms, stress ECG Test (exercise Electrocardiogram or treadmill test), Holter devices, long-duration Holter devices, event recorders, insertable cardiac monitors, 6,3,2,1-lead ECG wearables, textile electrodes and patches, smartwatches, cardiac monitors, cardiac telemetries, hemodynamic and electrophysiology recording system (i.e., polygraphs), automatic external defibrillator (AED), semi-automatic defibrillator (DESA), home telemonitoring systems and other similar devices.
Criteria

Inclusion Criteria:

  • Patient presenting relevant cardiac arrhythmias and cardiac patterns (including supraventricular tachycardias, abnormal ECG patterns, ventricular tachycardias, ventricular fibrillation, pulseless electrical activity or asystole among others) that have been recorded with at least one short-term ECG medical device according to guidelines with ≥1 signal-channel.
  • Patient with suspected or diagnosed acute/chronic cardiac diseases (including patients with heart failure, patients with history of cardiac arrhythmias, patients with probable coronary artery diseases, patients with cardiomyopathies, patients with pacemakers or implantable cardioverter-defibrillators (ICD), patients with indication of pacemaker or ICD in current or short-term phase, patients participating in other interventional clinical investigation, patients with hemodynamic instability or acute coronary syndromes, pregnant patients, patients with cancer and chemotherapy, patients with life-expectancy lower than 24 months, patients with in or out-of-hospital cardiac arrest with ventricular fibrillation as first documented rhythm).
  • At least one ECG tracing that can be exported in raw data.
  • Signed informed consent. Patients unable to consent, it will be requested to an authorized relative.

Exclusion Criteria:

  • Unwillingness or inability to sign study written informed consent.
  • Unavailable or suboptimal quality of the electrocardiographic signal in raw data.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05890716


Contacts
Layout table for location contacts
Contact: Manuel Marina-Breysse, MSc, MD +34618103160 manuel.marina@idoven.ai
Contact: Raquel Toribio-Fernández, PhD +34618103160 raquel.toribio@idoven.ai

Locations
Layout table for location information
Spain
Hospital General Universitario de Ciudad Real Recruiting
Ciudad Real, Spain, 13005
Contact: Jesús Piqueras, MD         
Idoven 1903 S.L. Recruiting
Madrid, Spain, 28002
Contact: Manuel Marina-Breysse, MsC       manuel.marina@idoven.ai   
Contact: Raquel Toribio-Fernández, PhD       raquel.toribio@idoven.ai   
Hospital Clínico San Carlos Recruiting
Madrid, Spain, 28040
Contact: David Filgueiras, MD         
Hospital Universitario General de Villalba Recruiting
Madrid, Spain, 28400
Contact: María De La Parte, MD         
Hospital Universitario del Henares Recruiting
Madrid, Spain, 28822
Contact: Daniel Corrochano, MD         
Sponsors and Collaborators
Idoven 1903 S.L.
Fundación de Investigación en Red en Enfermedades Cardiovasculares
Spanish Society of Cardiology
Investigators
Layout table for investigator information
Principal Investigator: María De La Parte, MD Idoven 1903 S.L.
Publications:

Layout table for additonal information
Responsible Party: Idoven 1903 S.L.
ClinicalTrials.gov Identifier: NCT05890716    
Other Study ID Numbers: 1903/21
First Posted: June 6, 2023    Key Record Dates
Last Update Posted: June 8, 2023
Last Verified: June 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Idoven 1903 S.L.:
Artificial intelligence
Cardiac arrhythmias
Heart disease
Cardiac electrical signals
Electrocardiogram
Electrogram
Additional relevant MeSH terms:
Layout table for MeSH terms
Cardiomyopathies
Arrhythmias, Cardiac
Death, Sudden, Cardiac
Death
Heart Diseases
Cardiovascular Diseases
Heart Arrest
Pathologic Processes
Death, Sudden